Incyte Corporation - Common Stock (NQ:INCY)

115.30 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

29 30 Next >

Incyte to Report First Quarter Financial Results

April 11, 2023

From Incyte

Via Business Wire

S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday ↗

April 10, 2023

Micron and Charles Schwab were among the top performers.

Via Investor's Business Daily

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target ↗

April 10, 2023

Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗

April 10, 2023

Via Benzinga

What 13 Analyst Ratings Have To Say About Incyte ↗

March 28, 2023

Via Benzinga

Incyte Stock Dives On Surprise Rejection For Updated Jakafi ↗

March 24, 2023

The company had hoped to gain approval for an extended-release version of its biggest drug.

Via Investor's Business Daily

Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday ↗

April 10, 2023

Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to...

Via Benzinga

Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)

March 27, 2023

From Incyte

Via Business Wire

Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' ↗

March 24, 2023

Via Benzinga

Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets

March 23, 2023

From Incyte

Via Business Wire

Analyst Expectations for Incyte's Future ↗

March 07, 2023

Via Benzinga

Incyte's Return On Capital Employed Overview ↗

February 08, 2023

Via Benzinga

Analyst Ratings for Incyte ↗

February 08, 2023

Via Benzinga

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗

March 23, 2023

Via Benzinga

Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

March 22, 2023

From Incyte

Via Business Wire

7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗

March 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.

Via InvestorPlace

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

March 18, 2023

From Incyte Corporation

Via Business Wire

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

March 18, 2023

From Incyte Corporation

Via Business Wire

Why Shares of MacroGenics Climbed Thursday ↗

March 16, 2023

The cancer-focused biotech delivered a strong earnings report.

Via The Motley Fool

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

March 14, 2023

From Incyte Corporation

Via Business Wire

Which S&P 500 Stocks Look Most Attractive Now? ↗

March 08, 2023

Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH.

Via Talk Markets

Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting

March 06, 2023

From Incyte

Via Business Wire

Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns ↗

March 06, 2023

Via Benzinga

Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis

March 03, 2023

From Incyte

Via Business Wire

Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents

February 24, 2023

From Incyte Corporation

Via Business Wire

Incyte to Present at Upcoming Investor Conference

February 16, 2023

From Incyte

Via Business Wire

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

February 10, 2023

From Incyte

Via Business Wire

Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone ↗

February 07, 2023

Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.

Via Investor's Business Daily

Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst ↗

February 07, 2023

Via Benzinga

Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs

February 07, 2023

From Incyte

Via Business Wire

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.